Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Emerson C Perin

Showing results (81-90 of 109) with videos related to

Pageof 11
Sort By:
American Heart Journal|December 3, 2014
Rationale and design for PACE: patients with intermittent claudication injected with ALDH bright cellsEmerson C Perin, Michael Murphy, John P Cooke, et al.
Journal of the American College of Cardiology|March 1, 2023
Randomized Trial of Targeted Transendocardial Mesenchymal Precursor Cell Therapy in Patients With Heart FailureEmerson C Perin, Kenneth M Borow, Timothy D Henry, et al.
American Heart Journal|June 23, 2014
Adipose-derived regenerative cells in patients with ischemic cardiomyopathy: The PRECISE TrialEmerson C Perin, Ricardo Sanz-Ruiz, Pedro L Sánchez, et al.
Circulation|January 12, 2005
Mesenchymal stem cells differentiate into an endothelial phenotype, enhance vascular density, and improve heart function in a canine chronic ischemia modelGuilherme V Silva, Silvio Litovsky, Joao A R Assad, et al.
Cardiovascular Research|August 13, 2021
Recommendations for nomenclature and definition of cell products intended for human cardiovascular useDoris A Taylor, Lourdes Chacon-Alberty, Luiz C Sampaio, et al.
Texas Heart Institute Journal|November 26, 2004
Catheter-based transendocardial delivery of autologous bone-marrow-derived mononuclear cells in patients listed for heart transplantationGuilherme V Silva, Emerson C Perin, Hans F R Dohmann, et al.
ESC Heart Failure|March 2, 2021
Reparative cell therapy for the heart: critical internal appraisal of the field in response to recent controversiesThomas J Povsic, Ricardo Sanz-Ruiz, Andreu M Climent, et al.
Circulation|September 15, 2004
Improved exercise capacity and ischemia 6 and 12 months after transendocardial injection of autologous bone marrow mononuclear cells for ischemic cardiomyopathyEmerson C Perin, Hans F R Dohmann, Radovan Borojevic, et al.
Circulation|April 17, 2013
Phase II clinical research design in cardiology: learning the right lessons too well: observations and recommendations from the Cardiovascular Cell Therapy Research Network (CCTRN)Joshua M Hare, Roberto Bolli, John P Cooke, et al.
American Heart Journal|June 19, 2018
Rationale and Design of the SENECA (StEm cell iNjECtion in cAncer survivors) TrialRoberto Bolli, Joshua M Hare, Timothy D Henry, et al.
Pageof 11

Showing results (81-90 of 109) with videos related to

Sort By:
Pageof 11
American Heart Journal|December 3, 2014
Rationale and design for PACE: patients with intermittent claudication injected with ALDH bright cellsEmerson C Perin, Michael Murphy, John P Cooke, et al.
Journal of the American College of Cardiology|March 1, 2023
Randomized Trial of Targeted Transendocardial Mesenchymal Precursor Cell Therapy in Patients With Heart FailureEmerson C Perin, Kenneth M Borow, Timothy D Henry, et al.
American Heart Journal|June 23, 2014
Adipose-derived regenerative cells in patients with ischemic cardiomyopathy: The PRECISE TrialEmerson C Perin, Ricardo Sanz-Ruiz, Pedro L Sánchez, et al.
Circulation|January 12, 2005
Mesenchymal stem cells differentiate into an endothelial phenotype, enhance vascular density, and improve heart function in a canine chronic ischemia modelGuilherme V Silva, Silvio Litovsky, Joao A R Assad, et al.
Cardiovascular Research|August 13, 2021
Recommendations for nomenclature and definition of cell products intended for human cardiovascular useDoris A Taylor, Lourdes Chacon-Alberty, Luiz C Sampaio, et al.
Texas Heart Institute Journal|November 26, 2004
Catheter-based transendocardial delivery of autologous bone-marrow-derived mononuclear cells in patients listed for heart transplantationGuilherme V Silva, Emerson C Perin, Hans F R Dohmann, et al.
ESC Heart Failure|March 2, 2021
Reparative cell therapy for the heart: critical internal appraisal of the field in response to recent controversiesThomas J Povsic, Ricardo Sanz-Ruiz, Andreu M Climent, et al.
Circulation|September 15, 2004
Improved exercise capacity and ischemia 6 and 12 months after transendocardial injection of autologous bone marrow mononuclear cells for ischemic cardiomyopathyEmerson C Perin, Hans F R Dohmann, Radovan Borojevic, et al.
Circulation|April 17, 2013
Phase II clinical research design in cardiology: learning the right lessons too well: observations and recommendations from the Cardiovascular Cell Therapy Research Network (CCTRN)Joshua M Hare, Roberto Bolli, John P Cooke, et al.
American Heart Journal|June 19, 2018
Rationale and Design of the SENECA (StEm cell iNjECtion in cAncer survivors) TrialRoberto Bolli, Joshua M Hare, Timothy D Henry, et al.
Pageof 11